Company Overview
Merck & Co Inc is a US-based pharmaceuticals company listed on the New York Stock Exchange. It develops and markets prescription medicines, vaccines, and animal health products. The company’s portfolio spans oncology, vaccines, infectious diseases, and cardiometabolic therapies. Market capitalization stands near USD 287 billion.
Analysis of recent data
FundamentalsIn reported USD figures for 2025, Merck generated revenue of 65.01 billion and net income of 18.26 billion. The trailing‑twelve‑month net profit margin was 28.08%, while operating margin reached 32.64%. Revenue growth of 1.31% year over year indicates a mature but steady top line.
Investment spending remains active, with 4.11 billion in capital expenditures and 2.79 billion in depreciation and amortization. Cash holdings of 14.57 billion against 5.18 billion in total debt provide balance‑sheet flexibility for continued reinvestment.
Return on equity of 36.19% and a gross margin of 78.55% highlight strong profitability. However, EBIT and free‑cash‑flow proxies are not provided, limiting visibility on reinvestment returns.
Valuation
DCF / MultiplesAt a share price of 115.91 USD, the market appears to discount a restrained long‑term outlook relative to intrinsic value estimates. The DCF analysis indicates upside potential, implying that current pricing reflects cautious growth assumptions.
High operating margin and strong cash reserves suggest internal capacity to fund reinvestment, which could support value expansion if growth accelerates.
Conclusion
TakeawayMerck shows a solid financial base and strong profitability. The market seems cautious about its growth potential. Continued reinvestment could enhance long‑term returns. Investors may find patience worthwhile as reinvestment compounds over time.